Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 7/20 | 0.39 |
| ▸ | CES1 | P23141 | 6/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799458 | 1.00 | CES2 (0.46) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL13328745 | 1.00 | CES2 (0.46) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL13826935 | 0.97 | CES2 (0.43) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL798836 | 0.88 | TSHR (0.35) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL15851484 | 0.87 | CES2 (0.42) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL16473079 | 0.84 | CES2 (0.39) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL18484329 | 0.82 | CES1 (0.48) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL18465760 | 0.82 | CES1 (0.48) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL28725235 | 0.82 | CES2 (0.38) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL6037238 | 0.78 | CES2 (0.46) | CES2LPAR1LPAR3TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318656-B2 | Production processes and systems, compositions, surfactants, monomer units, metal complexes, phosphate esters, glycols, aqueous film forming foams, and foam stabilizers | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120071689-A1 | PRODUCTION PROCESSES AND SYSTEMS, COMPOSITIONS, SURFACTANTS, MONOMER UNITS, METAL COMPLEXES, PHOSPHATE ESTERS, GLYCOLS, AQUEOUS FILM FORMING FOAMS, AND FOAM STABILIZERS | E.I. DU PONT DE NEMOURS AND COMPANY CHEMTURA CORPORATION (US) | 2012-03-22 | — | — | US | disclosed |
| US-7943567-B2 | Production processes and systems, compositions, surfactants, monomer units, metal complexes, phosphate esters, glycols, aqueous film forming foams, and foam stabilizers | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20080009655-A1 | Production Processes and Systems, Compositions, Surfactants, Monomer Units, Metal Complexes, Phosphate Esters, Glycols, Aqueous Film Forming Foams, and Foam Stabilizers | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-01-10 | — | — | US | disclosed |
| US-20070149437-A1 | Production processes and systems, compositions, surfactants, monomer units, metal complexes, phosphate esters, glycols, aqueous film forming foams, and foams stabilizers | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149437-A1 | Production processes and systems, compositions, surfactants, monomer units, metal complexes, phosphate esters, glycols, aqueous film forming foams, and foams stabilizers | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009655-A1 | Production Processes and Systems, Compositions, Surfactants, Monomer Units, Metal Complexes, Phosphate Esters, Glycols, Aqueous Film Forming Foams, and Foam Stabilizers | FOS, AFF4, AFF1 | CES2 1138/4885LPAR1 2330/4885LPAR3 994/4885 |
| US-20120071689-A1 | PRODUCTION PROCESSES AND SYSTEMS, COMPOSITIONS, SURFACTANTS, MONOMER UNITS, METAL COMPLEXES, PHOSPHATE ESTERS, GLYCOLS, AQUEOUS FILM FORMING FOAMS, AND FOAM STABILIZERS | FOS, AFF4, AFF1 | CES2 1095/4885LPAR1 2421/4885LPAR3 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.